These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 36295656)

  • 1. Non-Transfusion-Dependent Thalassemia: A Panoramic Review.
    Shash H
    Medicina (Kaunas); 2022 Oct; 58(10):. PubMed ID: 36295656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-transfusion-dependent thalassemia and thalassemia intermedia: epidemiology, complications, and management.
    Vichinsky E
    Curr Med Res Opin; 2016; 32(1):191-204. PubMed ID: 26479125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-Transfusion-Dependent Thalassemia: An Update on Complications and Management.
    Sleiman J; Tarhini A; Bou-Fakhredin R; Saliba AN; Cappellini MD; Taher AT
    Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29316681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Morbidities in non-transfusion-dependent thalassemia.
    Saliba AN; Taher AT
    Ann N Y Acad Sci; 2016 Mar; 1368(1):82-94. PubMed ID: 27186941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Iron overload in thalassemia: different organs at different rates.
    Taher AT; Saliba AN
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):265-271. PubMed ID: 29222265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deferasirox for the treatment of iron overload in non-transfusion-dependent thalassemia.
    Taher AT; Temraz S; Cappellini MD
    Expert Rev Hematol; 2013 Oct; 6(5):495-509. PubMed ID: 24083402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How I treat non-transfusion-dependent β-thalassemia.
    Saliba AN; Musallam KM; Taher AT
    Blood; 2023 Sep; 142(11):949-960. PubMed ID: 37478396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iron chelation therapy for non-transfusion-dependent thalassemia (NTDT): a status quo.
    Taher AT; Musallam KM; Viprakasit V; Porter JB; Cappellini MD
    Blood Cells Mol Dis; 2014; 52(2-3):88-90. PubMed ID: 24041597
    [No Abstract]   [Full Text] [Related]  

  • 9. New therapeutic targets in transfusion-dependent and -independent thalassemia.
    Cappellini MD; Motta I
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):278-283. PubMed ID: 29222267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Profile of deferasirox for the treatment of patients with non-transfusion-dependent thalassemia syndromes.
    Ricchi P; Marsella M
    Drug Des Devel Ther; 2015; 9():6475-82. PubMed ID: 26719673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thalassemia Intermedia: Chelator or Not?
    Lee YC; Yen CT; Lee YL; Chen RJ
    Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Iron Overload and Chelation Therapy in Non-Transfusion Dependent Thalassemia.
    Bou-Fakhredin R; Bazarbachi AH; Chaya B; Sleiman J; Cappellini MD; Taher AT
    Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29261151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Iron Chelation Therapy as a Modality of Management.
    Aydinok Y
    Hematol Oncol Clin North Am; 2018 Apr; 32(2):261-275. PubMed ID: 29458731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deferasirox: a review of its use for chronic iron overload in patients with non-transfusion-dependent thalassaemia.
    Shirley M; Plosker GL
    Drugs; 2014 Jun; 74(9):1017-27. PubMed ID: 24919862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-transfusion-dependent thalassemias.
    Musallam KM; Rivella S; Vichinsky E; Rachmilewitz EA
    Haematologica; 2013 Jun; 98(6):833-44. PubMed ID: 23729725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Current management of thalassemia intermedia].
    Thuret I
    Transfus Clin Biol; 2014 Nov; 21(4-5):143-9. PubMed ID: 25282488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treating iron overload in patients with non-transfusion-dependent thalassemia.
    Taher AT; Viprakasit V; Musallam KM; Cappellini MD
    Am J Hematol; 2013 May; 88(5):409-15. PubMed ID: 23475638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-transfusion Dependent Thalassemias: A Developing Country Perspective.
    Mukherjee S; Das RR; Raghuwanshi B
    Curr Pediatr Rev; 2015; 11(2):87-97. PubMed ID: 26133180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction of Transfusion and Iron Chelation in Thalassemias.
    Porter JB; Garbowski MW
    Hematol Oncol Clin North Am; 2018 Apr; 32(2):247-259. PubMed ID: 29458730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increasing prevalence of thalassemia in America: Implications for primary care.
    Sayani FA; Kwiatkowski JL
    Ann Med; 2015; 47(7):592-604. PubMed ID: 26541064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.